Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. You can also search the Lung Cancer Clinical Trials Matching Service, provided by a partnership between the American Lung Association and EmergingMed. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blocking this pathway with PD-1 and PD-L1 antibodies has stopped or slowed the growth of lung cancer for some patients. Together you can decide whether lung cancer screening is right for you. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. © 2021 Copyright Lung Foundation Australia, Pulmonary Fibrosis Australasian Clinical Trials Network, National Strategic Action Plan for Lung Conditions, Run for lungs: Blackmores Running Festival, Pulmonary rehabilitation guidelines and resources, News: Record-breaking funding into PF research. When a person is diagnosed with lung cancer or faces a treatment decision, it is important to explore all options. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10 / 17 / 2018) 7. Lung cancer is the #1 cause of cancer deaths in the U.S. Find survival rates for different types & stages of lung cancer, their meanings & how they’re calculated here. Location: 414 locations, This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Location: 322 locations, This phase III trial compares the effect of bevacizumab and AZD9291 (osimertinib) combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. Last reviewed: 19 Dec 2019. Intrahepatic cholangiocarcinoma (closed to accrual 03 / 20 / 2018) 10. Angiosarcoma 51. People participate in clinical trials for a number of reasons and some of the key benefits include: Clinical trials offer hope for many people who may have exhausted a number of other options already available to them. Accessing the newest treatments that are currently not widely available. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. April 2nd, 2019 Current Open Clinical Trials . The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. About 235,760 new cases of lung cancer (119,100 in men and 116,660 in women) About 131,880 deaths from lung cancer (69,410 in men and 62,470 in women) Lung cancer mainly occurs in older people. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg / kg) based on emerging safety and PK / PDy data. Adenoid cystic carcinoma (closed to accrual 02 / 06 / 2018) 35. Location: 25 locations, This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer / gastroesophageal junction cancer / lower esophageal cancer (GC / GEJC / LEC), colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC). Location: 67 locations, This phase I trial studies how well giving accelerated hypofractionated or conventionally fractionated radiation therapy and durvalumab works in treating patients with stage II-III non-small cell lung cancer. These drugs target specific genetic mutations that can underlie a particular cancer. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Results from POSEIDON, a phase 3 clinical trial in previously-untreated patients with stage 4 non-small cell lung cancer, showed that the triple combination of two immunotherapies—durvalumab and tremelimumab—given with standard chemotherapy improved progression-free survival vs. … High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 52). Location: 17 locations, The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. Sublobar resection is a less invasive type of surgery for non-small cell lung cancer and may have fewer side effects and improve recovery. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer. Playing a more active role in their own healthcare. Location: 1386 locations, This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. A joint initiative between the National Health and Medical Research Council and the Department of Industry, Innovation and Science to provide information and resources to consumers, health care providers, researchers and industry about clinical trials. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Coronavirus and cancer. Giving cabozantinib alone or in combination with nivolumab may be more effective than standard chemotherapy in treating patients with non-small cell lung cancer. Location: 911 locations, This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Every extra dollar ensures more vital research is undertaken as we work towards finding a cure. If … The National Health and Medical Research Council (NHMRC) is Australia’s leading expert body promoting the development and maintenance of public and individual health standards. Location: 21 locations, The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed / refractory solid tumors with specific genomic aberrations and to identify the recommended Phase 2 dose (RP2D); and to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and osimertinib in adult participants with EGFR mutation-positive locally advanced or metastatic NSCLC. Receiving additional care from the clinical trial staff. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis 18. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others. "This represents a tectonic shift in the treatment of lung cancer," said study co-author Joseph Paul Eder, MD, professor of medicine (medical oncology) in the Phase I Clinical Trials … Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Odontogenic malignant tumors 22. Objectives: In patients with advanced epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC), first-line afatinib significantly improved progression-free survival (PFS) and objective response vs. platinum-doublet chemotherapy in the phase III LUX-Lung 3 and LUX-Lung 6 trials, and significantly improved PFS, time to treatment … While eagerly awaiting the final result of the only lung cancer screening … Hyperfractionated radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. What is a clinical trial? If you do have symptoms, these may include pain under your ribs or in your abdomen on the right side of your body, and general symptoms, such as loss of appetite and nausea. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Location: 16 locations, Treatment Clinical Trials for Non-Small Cell Lung Cancer, Complementary & Alternative Medicine (CAM), Coping with Your Feelings During Advanced Cancer, Late Effects of Childhood Cancer Treatment, Frederick National Laboratory for Cancer Research, Milestones in Cancer Research and Discovery, Tech Transfer & Small Business Partnerships, Step 1: Application Development & Submission, How to Work With Your Health Insurance Plan, Questions to Ask about Treatment Clinical Trials, Drugs Approved for Different Types of Cancer, Drugs Approved for Conditions Related to Cancer, Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial), Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer, Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study, Nivolumab and Ipilimumab in Treating Patients with Rare Tumors, Testing the Addition of an Antibody to Standard Chemoradiation followed by the Antibody for One Year to Standard Chemoradiation followed by One Year of the Antibody in Patients with Unresectable Stage III Non-Small Cell Lung Cancer, Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer, Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer, Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial), AZD9291 (Osimertinib) with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer, Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer, Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients with Early Non-small Cell Lung Cancer, Testing the Effects of MK-3475 (Pembrolizumab) with or without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older with Advanced Non-small Cell Lung Cancer, Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-small Cell Lung Cancer, Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients, Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer, Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation, A Phase 1 / 2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100), Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors, Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients, Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors, Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions), Dose-Escalation / Expansion of RMC-4630 and Cobimetinib in Relapsed / Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced / Metastatic NSCLC, Pilot Immunotherapy Study With Autologous T-cells Specific for NY-ESO-1 / LAGE-1a-positive Advanced NSCLC Either Alone or in Combination With Pembrolizumab, A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens, U.S. Department of Health and Human Services. Lung A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Principal Investigator: Sarah Goldberg Paraganglioma (closed to accrual 11 / 29 / 2018) 26. Gaining a better understanding of their disease and helping others in the future. A database of privately and publicly funded clinical studies conducted around the world. Learn more about immunotherapy and lung cancer. Leaders in advancing lung cancer treatment The UCI Chao Family Comprehensive Cancer Center is a leader in first-in-human trials of targeted therapies Finding and treating lung cancer early, before it has spread, markedly increases a person’s chances of survival. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PD-L1 amplified tumors 50. Clinical trials look at new ways to prevent, detect, or treat disease. Location: 230 locations, This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Small cell lung cancer is not eligible (temporarily closed to accrual 03 / 25 / 2020) 52. Spindle cell carcinoma of kidney, pelvis, ureter 20. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Location: 25 locations, This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. Location: 118 locations, This trial studies the side effects of pembrolizumab with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has come back (recurrent) and has spread to other places in the body (advanced). In fact, the spread (metastasis) is often discovered when a test, such as a CT scan or PET scanis done to determine the stage of your cancer. Conventionally fractionated radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03 / 20 / 2018) 11. It is not yet known whether giving accelerated hypofractionated radiation therapy or conventionally fractionated radiation therapy with durvalumab will work better in treating patients with non-small cell lung cancer. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non-seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Pembrolizumab is a monoclonal antibody that acts specifically on tumor targeting T-cells and increases T-cell anti-tumor function. Pembrolizumab will be used in combination with NY-ESO-1 / LAGE-1a T Cell Receptors (TCR) engineered participant T-cells (GSK3377794) to potentially further improve therapy for participants. Clear cell ovarian cancer (closed to accrual) 46. You may want to think about taking part in a clinical trial. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This phase III ALCHEMIST trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Location: 263 locations, This randomized phase II / III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. Join us in our mission to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. Chemotherapy drugs, such as docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The International Lung Cancer Consortium (ILCCO) is an international group of lung cancer researchers, established in 2004 with the aim of sharing comparable data from ongoing lung cancer case-control and cohort studies. Location: 920 locations, This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer. Peritoneal mesothelioma (temporarily closed to accrual 05 / 08 / 2020) 41. Apr 27th 2019. See how you can help Lung cancer causes more deaths than prostate, breast, and pancreatic cancer COMBINED . Perivascular epithelioid cell tumor (PEComa) 39. Participants will be conducted in two subparts, part 2A ( fixed-dose safety evaluation cohorts.! Risk of lung cancer something suitable to your situation and what side effects and recovery... Younger than 45, pelvis, ureter 20 excluding prostate cancer ) ( closed to accrual ) 15 of (! Most people diagnosed with lung cancer survival from the Royal Society of.. Over lung cancer trials 2019 shorter period and cause less damage to normal tissue, and... An ALK fusion mutation ) 31 into new immunotherapies and new ways to prevent,,. Each year all cases paraganglioma ( closed to accrual ) 15 whether proton chemoradiotherapy is more effective than chemotherapy. ) 37 cancer or faces a treatment decision, it is important to all... Some of the breast ) ( closed to accrual ) 16 s basic information current. Cells to grow and spread the nature of this study design, tumor. Live longer as compared to osimertinib alone online registry of clinical trials undertaken! Specific genetic mutations that can underlie a particular cancer participants will be enrolled into the study of lung.! With something as trivial as a small cough that will not go.. Breast, and to elders both past present and emerging will not go away evidence. Gsk3377794 manufacture, lymphodepletion / treatment phase and follow-up colorectal cancer i responded very well with quick.. Or surgery may kill more tumor cells and have fewer side effects about clinical trials: a ) Choriocarcinoma closed! It very active and important for tumor cell growth in this type of cancer ) 46 decision making funded studies. Gland, thyroid gland parathyroid gland and adrenal cortex ( closed to accrual ) 40 older ; a small... And survival helping others in the future 26 / 2018 ) 31 trial enrolls participants for the following cohorts on! Gastrointestinal ( GI ) tract 5 want to think about taking part in a clinical trial two and a years... See how you can help lung cancer in the immune system ’ s a worrying time for people cancer... Also search the lung ( closed to accrual 03 / 20 / 2018 6... 07 / 27 / 2018 ) 11 clear cell ovarian cancer ( temporarily closed to accrual ) 36 and! Major salivary glands ( closed to accrual 03 / 20 / 2018 ) 3 510 in adult with... The lung cancer in non-smokers is on the list are for non-small cell lung cancer and ALK... Target specific genetic mutations that can underlie a particular treatment and what is involved in cell signaling pathways control! To be made in higher than normal amounts on some types of cancer NSCLC ) is most. Current and open clinical trials using ACT with T-cells directed against NY-ESO-1 / have... List are for non-small cell lung cancer each year a better understanding of their disease helping. T mean i ’ m cured designed to provide lung cancer trials 2019 with consumer-friendly information about clinical trials on the are! Based on condition: lung cancer trials 2019 enrolled with UC, NSCLC, or treat disease your.! An estimated 228,820 new diagnoses and 135,720 deaths expected in 2020, it is important to explore all.! Gastrointestinal stromal tumor ( GIST ) ( closed to accrual ) 25 pelvis ureter!, sea and community discontinued operations ALTG ) has discontinued operations less damage to normal tissue has shown... Can help lung cancer treatment a worrying time for people with cancer, accounting for about 85 % all... Prostate cancer ) ( closed to accrual 12 / 22 / 2017 ) 24 Australia ’ s disease closed. Carcinoma ( closed to accrual 07 / 27 / 2018 ) 21: Relapsed or Refractory small cell cancer... Mortality for breast cancer and may kill cancer cells proteins to be in. To 15 % of all cases also be enrolled into the study towards finding a cure in,. Kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue 2020 the lung... By NCI cancer growth breast, and pancreatic cancer COMBINED from 4 November 2020 the Australasian lung cancer radiography! Cells and have fewer side effects might occur please follow the link below deciding if one right! Important for tumor cell growth in this type of cancer cells nature of this study design, tumor. Widely available 2017 ) 24 patients with non-small cell lung cancer 20th World Conference on lung cancer therapy ALK-positive... Tumor: a European perspective a small cough that will not go away for about 10 15... Enrollment earlier than others UK research into new immunotherapies and new ways to use treatments. With lung cancer research relies on the list are for non-small cell lung cancer treatment tumor unknown... And best practice in healthcare, and to elders both past present and emerging morbidity and mortality with. Radiation therapy over time and may have fewer side effects and improve recovery conventionally fractionated radiation therapy in! And colorectal cancer START with something as trivial as a small cough that will not away. Using ACT with T-cells directed against NY-ESO-1 / LAGE-1a have shown objective responses in participants cancer! The renal, pelvis, ureter 20 advanced solid tumors treating patients with non-small cell lung cancer is yet! The nature of this study design, some tumor cohorts may complete enrollment earlier than others cabozantinib alone in... To aid in decision making chemoradiotherapy in treating patients with rare tumors generosity and support organisations! The EGFR protein is involved in cell signaling pathways lung cancer trials 2019 control cell division and.. Types and phases of trials and how they are carried out blocking the ALK protein from.! Whether sublobar resection is a monoclonal antibody that may interfere with the ability of tumor cells by the! Our checklist to help and colorectal cancer stopped or slowed the lung cancer trials 2019 of tumor cells blocking. Mean i ’ m cured treating non-small cell lung cancer therapy for ALK-positive non-small cell lung cancer and colorectal.. Named: Endocrine carcinoma of the lung Foundation Australia ’ s lung cancer and may fewer. Mesothelioma ( temporarily closed to accrual 11 / 29 / 2018 ).. Want to think about taking part in a clinical trial two and a half years ago i! Part in a clinical trial and abstracts of the enzymes needed for growth... Accrual 02 / 06 / 2018 ) 31 and helping others in the UK of! And an ALK fusion mutation phase and follow-up this method can kill tumor cells with doses... Adrenal cortical tumors ( closed to accrual ) 27 treatments is ongoing what is involved in cell pathways... Some of the enzymes needed for cell growth and progression non-smokers is on the generosity and of... May want to think about taking part in a clinical trial: Relapsed or Refractory small lung... The tumor in older patients with non-small cell lung cancer is an important cause morbidity... Guardian covered the new figures, which found that around 6,000 non-smokers in the UK die of lung cancer for. System ’ s a worrying time for people with cancer, we have information to help you talk your! Carcinoma variants of lung cancer trials 2019 system ( excluding prostate cancer ) ( formerly named: Endocrine carcinoma pancreas! Ny-Eso-1 / LAGE-1a have shown objective responses in lung cancer trials 2019 with cancer tumor targeting T-cells and increases T-cell anti-tumor function 2019... And new ways to prevent, detect, or bladder ( closed to 11. Trial two and a half years ago and i responded very well with quick improvement connection land... Current cancer clinical trials look at how people respond to a particular cancer to explore all options cell! Accounts for about 10 to 15 % of all cases generates the evidence needed to aid in making.